| Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
| Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] | Technology appraisal guidance | |
| Vosoritide for treating achondroplasia in people 4 months and over ID6488 | Technology appraisal guidance | TBC |
| Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470] | Technology appraisal guidance | |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] | Technology appraisal guidance | TBC |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] | Technology appraisal guidance | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | |